EUVIMEDOpdag EUVIMED
Open access

Metabolism, Pharmacokinetics, and Tissue Distribution of a Selective FK506-Binding Protein 12 F36V Mutant Degrader in Mice

Shenzhi Zhou, Xuan Qin iD, Kevin Tran, Jian Wang iD, Xingyu Ji, Kevin R MacKenzie iD, Srinivas Chamakuri iD, Jin Wang iD, Feng Li iD

ACS Pharmacology & Translational Science · 2025-12-12 · 8 (12) · 4410-4422

DOI: 10.1021/acsptsci.5c00643 ↗

At a glance

Journal article in ACS Pharmacology & Translational Science, published online on 2025-11-11. Written by Shenzhi Zhou and 8 co-authors. Institution: Center for Drug Discovery, Baylor College of Medicine, Houston, Texas 77030, United States. Cited 6 times so far (Crossref); 24 references. The full text is freely available in PubMed Central. Funded by: NICHD NIH HHS, U.S. Department of Health and Human Services.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

dTAG-13 is a heterobifunctional molecule that induces proteasomal degradation of FKBP12F36V-tagged proteins and is widely used in the dTAG system. To better understand its in vivo behavior, we investigated its metabolism in vitro and its metabolism, pharmacokinetics, and tissue distribution time-course in mice. dTAG-13 was rapidly absorbed within 40 min and distributed to most tissues (although not brain) with a half-life of 3.1 h. We identified 20 metabolites that resulted from demethylation, amide hydrolysis, O-dealkylation, ester cleavage, and hydroxylation products. No phase II metabolites were detected. Demethylation was predominant in the liver, while hydrolysis metabolites were abundant in plasma and widely distributed. Both NADPH-dependent and hydrolysis pathways contributed to its metabolism, with CYP3A playing a moderate role in dTAG-13 degradation. These findings support the suitability of dTAG-13 for short-term protein degradation studies, while its limited brain penetration and rapid clearance highlight the need for improved analogs. This study provides foundational insights into dTAG-13 disposition for rational in vivo use.

Subjects

Author keywords

LC-MSdTAG-13metabolismmetabolomicspharmacokineticstissue distribution

Authors and institutions

  • Center for Drug Discovery, Baylor College of Medicine, Houston, Texas 77030, United States.
  • Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, United States.
  • NMR and Drug Metabolism Core, Advanced Technology Cores, Baylor College of Medicine, Houston, Texas 77030, United States.
  • Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.
  • Center for NextGen Therapeutics, Baylor College of Medicine, Houston, Texas 77030, United States.

ORCID profiles: Xuan Qin, Jian Wang, Kevin R MacKenzie, Srinivas Chamakuri, Jin Wang, Feng Li

Funding

  • NICHD NIH HHS
  • U.S. Department of Health and Human Services

Cite

APA

Zhou, S., Qin, X., Tran, K., Wang, J., Ji, X., MacKenzie, K. R., Chamakuri, S., Wang, J., & Li, F. (2025). Metabolism, Pharmacokinetics, and Tissue Distribution of a Selective FK506-Binding Protein 12 F36V Mutant Degrader in Mice. ACS Pharmacology & Translational Science, 8(12), 4410-4422. https://doi.org/10.1021/acsptsci.5c00643

Vancouver

Zhou S, Qin X, Tran K, Wang J, Ji X, MacKenzie KR, et al. Metabolism, Pharmacokinetics, and Tissue Distribution of a Selective FK506-Binding Protein 12 F36V Mutant Degrader in Mice. ACS Pharmacology & Translational Science. 2025;8(12):4410-4422. doi:10.1021/acsptsci.5c00643

BibTeX
@article{Zhou2025,
  author = {Zhou, Shenzhi and Qin, Xuan and Tran, Kevin and Wang, Jian and Ji, Xingyu and MacKenzie, Kevin R and Chamakuri, Srinivas and Wang, Jin and Li, Feng},
  title = {Metabolism, Pharmacokinetics, and Tissue Distribution of a Selective FK506-Binding Protein 12 F36V Mutant Degrader in Mice},
  journal = {ACS Pharmacology & Translational Science},
  year = {2025},
  volume = {8},
  number = {12},
  pages = {4410--4422},
  doi = {10.1021/acsptsci.5c00643}
}
Start for free →